Table IV.

Change in Lipid Parameters After 3 Months of Aromatase Inhibitor Therapy in the Lipid-Altering Medication Analysis (n = 95)

	Lipid-Altering Medication Cohort (n = 95)				Exemestane + Lipid-Altering Medication Group (n = 41)				Letrozole + Lipid-Altering Medication Group (n = 54)
	Baseline	3 Months	Change, Mean ± SD (%)	P Value	Baseline	3 Months	Change, Mean ± SD (%)	P Value	Baseline	3 Months	Change, Mean ± SD (%)	P Value
Total cholesterol, mg/dL	176 ± 32	168 ± 30	−7 ± 20 (4)	.001	180 ± 31	167 ± 30	−12 ± 22 (7)	.001	173 ± 32	169 ± 29	−3 ± 18 (2)	.172
HDL, mg/dL	54 ± 15	50 ± 13	−4 ± 7 (8)	<.001	54 ± 12	49 ± 12	−5 ± 8 (10)	<.001	54 ± 17	50 ± 15	−4 ± 7 (7)	.001
LDL, mg/dL	97 ± 26	95 ± 23	−3 ± 19 (3)	.186	100 ± 26	96 ± 24	−4 ± 21 (4)	.239	95 ± 27	93 ± 22	−2 ± 18 (2)	.502
LDL/HDL Ratio	1.9 ± 0.7	2.0 ± 0.7	0.1 ± 0.5 (5)	.071	1.9 ± 0.7	2.1 ± 0.6	0.2 ± 0.5 (10)	.123	1.9 ± 0.8	2.0 ± 0.7	0.1 ± 0.5 (5)	.310
TG, mg/dL	124 ± 59	120 ± 53	−4 ± 48 (3)	.463	129 ± 64	109 ± 43	−20 ± 54 (15)	.024	120 ± 55	128 ± 59	9 ± 40 (7)	.112

Values are shown as mean ± SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.